No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
TD Cowen Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals Inc (SNDX) Q4 2024 Earnings Call Highlights: Strong Product Launch and ...
Positive Outlook on Syndax Pharmaceuticals: Strong Market Presence and Strategic Growth Initiatives
Syndax Pharmaceuticals Price Target Raised to $39.00/Share From $35.00 by JP Morgan
Syndax Pharmaceuticals Is Maintained at Buy by Citigroup